Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:50:04 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:RNA from 2023-04-27 to 2024-04-26 - 38 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-22 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-27 09:00U:RNANews ReleaseAvidity Biosciences to Participate in Upcoming Investor Conferences
2024-03-21 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-04 07:00U:RNANews ReleaseAvidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR(TM) Trial
2024-02-29 12:00U:RNANews ReleaseAvidity Biosciences Honors Rare Disease Day(TM)
2024-02-29 07:00U:RNANews ReleaseAvidity Biosciences Announces Oversubscribed $400 Million Private Placement
2024-02-28 16:05U:RNANews ReleaseAvidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
2024-02-27 09:00U:RNANews ReleaseAvidity Biosciences to Participate in Upcoming Investor Conferences
2024-02-21 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-20 09:00U:RNANews ReleaseAvidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
2024-02-15 17:00U:RNANews ReleaseAvidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE ¢ „ ¢ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
2024-01-22 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-05 08:30U:RNANews ReleaseAvidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
2023-12-21 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-13 08:30U:RNANews ReleaseAvidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44 ¢ „ ¢ Trial for Duchenne Muscular Dystrophy
2023-11-28 06:30U:RNANews ReleaseAvidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC ¢ „ ¢ Platform Technology
2023-11-21 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-21 09:00U:RNANews ReleaseAvidity Biosciences to Participate in Upcoming Investor Conference
2023-11-08 16:05U:RNANews ReleaseAvidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights
2023-10-23 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-10-07 07:30U:RNANews ReleaseAvidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1
2023-09-26 09:00U:RNANews ReleaseAvidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society
2023-09-25 09:00U:RNANews ReleaseAvidity Biosciences to Participate in Upcoming Investor Conferences
2023-09-21 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-07 09:00U:RNANews ReleaseAvidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs
2023-08-31 09:00U:RNANews ReleaseAvidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference
2023-08-30 09:00U:RNANews ReleaseAvidity Biosciences to Participate in Upcoming Investor Conferences
2023-08-21 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-15 09:00U:RNANews ReleaseAvidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
2023-08-08 16:05U:RNANews ReleaseAvidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights
2023-07-21 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-21 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-20 09:00U:RNANews ReleaseAvidity Biosciences Joins with Patients, Caregivers and Healthcare Providers Globally to Support World Facioscapulohumeral Muscular Dystrophy (FSHD) Day
2023-06-08 09:00U:RNANews ReleaseAvidity Biosciences Announces Upcoming Presentations at the 30th Annual FSHD Society International Research Congress
2023-05-22 16:05U:RNANews ReleaseAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-17 07:00U:RNANews ReleaseAvidity Biosciences Announces FDA Eases Partial Clinical Hold on AOC 1001 Providing a Clear Path Forward to Finalize Pivotal Dose and Phase 3 Design in Adults with Myotonic Dystrophy Type 1
2023-05-09 16:05U:RNANews ReleaseAvidity Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
2023-04-27 15:40U:RNANews ReleaseAvidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA ¢ „ ¢ Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1